Sector: Health Care
Director information for CHARLES RIVER LABORATORIES INTERNA (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Abraham Ceesay | Chief Executive Officer of Rapport Therapeutics | 48 | ["nearly two decades of executive and public company biopharmaceutical industry experience"] | [] | 2026 |
| Craig B. Thompson | President Emeritus, Former President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center. Member of the Sloan Kettering Institute and the Department of Medicine, Memorial Sloan Kettering Cancer Center. | 73 | [] | [] | 2026 |
| Craig B. Thompson, M.D. | Director | 73 | ["Former President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center", "Oversees a research laboratory at Sloan Kettering Institute", "Former Director of Abramson Cancer Center at University of Pennsylvania", "Professor of Medicine and Cancer Biology at University of Pennsylvania", "Board member of Regeneron Pharmaceuticals, Inc.", "Former board member of Merck & Co. Inc.", "Member of Howard Hughes Medical Institute, M.D. Anderson Cancer Center, Ohio State University Comprehensive Cancer Center", "Member of Albert Lasker Medical Research Awards Prize Committee", "Elected member of National Academy of Sciences and National Academy of Medicine", "Founder of three biotechnology companies including Agios Pharmaceuticals"] | [] | 2026 |
| James C. Foster | Chair, President and CEO of Charles River Laboratories International, Inc.* | 75 | ["Joined in 1976 as General Counsel", "Held various staff and managerial positions", "Named President in 1991", "Chief Executive Officer in 1992", "Chair in 2000", "Depth of knowledge of operations", "Acute business judgment", "Extensive familiarity with competing businesses", "Lengthy experience with the company"] | [] | 2026 |
| Mark Enyedy | Former President and Chief Executive Officer of ImmunoGen, Inc. | 62 | ["more than three decades of combined general management, business development, and legal experience in the biotechnology industry", "significant M&A and capital markets experience", "public healthcare board experience"] | [] | 2026 |
| Martin W. Mackay | Co-Founder and Non-Executive Chair of Rallybio Corporation. Former Chief of R&D, AstraZeneca and Former Chief of R&D, Alexion Pharmaceuticals, Inc. | 70 | [] | [] | 2026 |
| Martin W. Mackay, Ph.D. | Non-Executive Chair | 70 | ["Co-founder of Rallybio Corporation", "Former Chief Executive Officer (2018-2023)", "Former Executive Chair (2023-2024)", "Global Head of Research & Development at Alexion Pharmaceuticals, Inc.", "President of R&D at AstraZeneca PLC", "Director of Novo Nordisk and SpringWorks Therapeutics", "Director of 5:01 Acquisition Corp."] | [] | 2026 |
| Nancy C. Andrews, M.D., Ph.D | Director | 67 | ["Accomplished physician", "Scientific researcher", "Professor", "Senior administrator at leading academic institutions and hospitals", "Extensive scientific leadership and expertise in oncology, genetics, and pediatric research", "Understanding of research and development process"] | [] | 2026 |
| Paul Graves | Former Chief Executive Officer of Rio Tinto Lithium | 55 | ["significant executive leadership and public company board experience", "investment banking and M&A expertise", "qualifies as an audit committee financial expert under SEC guidelines"] | [] | 2026 |
| Reshema Kemps-Polanco | Executive Vice President and Chief Commercial Officer, Novartis US | 53 | ["extensive healthcare business leadership knowledge", "deep industry experience at two of the top-10 global pharmaceutical companies", "demonstrated ability to oversee large commercial organizations across multiple therapeutic areas", "sales and marketing expertise", "over 25 years of experience in the life-sciences sector"] | ["Rutgers Cancer Institute Leadership Council", "Healthcare Businesswomen\u2019s Association (HBA) Global Advisory Board", "CEO Roundtable on Cancer"] | 2026 |
| Steven Barg | Global Co-Head of Engagement at Elliott Investment Management, L.P. | 64 | ["significant M&A and capital markets expertise", "public board experience in the CDMO/CRO space"] | [] | 2026 |
| Virginia M. Wilson | Retired Senior Executive Vice President and Chief Financial Officer, TIAA; Director | 71 | ["Over 30 years of financial management experience", "Certified Public Accountant", "Audit committee financial expert under SEC guidelines"] | [] | 2026 |
